Featuring an interview with Dr William K Oh, including the following topics:

Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
Radiopharmaceuticals for the treatment of mCRPC (16:53)
Available data on cabozantinib for mCRPC (24:38)
Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
Data surrounding adjuvant immunotherapy for MIBC (38:07)
Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
Implementation of emerging data in the treatment landscape of UC (41:56)

Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit